FOXO1：An Indicator for Prognosis of Lung Adenocarcinoma and Squamous Carcinoma from a Comprehensive Analysis of Bioinformatics

Abstract

Background Patients diagnosed with lung adenocarcinoma and lung squamous carcinoma typically face a poor clinical prognosis. There is an urgent need to identify biomarkers that can enhance the potential clinical prognoses and guide lung cancer treatment. FOXO1, a tumour suppressor, is frequently inactivated in various human cancers and may be correlated with patients' prognosis. Methods In this study, we utilised comprehensive online databases, including Oncomine, Kaplan-Meierplotter, and PrognoScan, to investigate the expression of FOXO1 and its relationship with patients' prognosis. To generate informative plots, we employed sophisticated analytical tools such as R-language and the Xiantao academic platform. Results Our findings revealed downregulation of FOXO1 expression in both lung adenocarcinoma and lung squamous carcinoma, which exhibited a significant positive correlation with overall survival and recurrence-free survival. Notably, in lung adenocarcinoma, the anti-tumour activity of FOXO1 appeared to be predominantly associated with central memory T cells, mast cells, T helper cells, and helper T cells 2. Conversely, in lung squamous carcinoma, the anti-tumour effect seemed to be related to central memory T cells, mast cells, macrophages, and gamma delta T cells. Conclusions Based on our results, FOXO1 shows potential as a prognostic marker for predicting the survival outcomes of patients with lung adenocarcinoma and lung squamous carcinoma. Further validation and exploration of FOXO1's role in these cancer types are warranted to advance our understanding and potentially improve clinical management strategies.